Michelle A. Blaskovich

4.0k total citations · 1 hit paper
44 papers, 3.3k citations indexed

About

Michelle A. Blaskovich is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Michelle A. Blaskovich has authored 44 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Molecular Biology, 26 papers in Oncology and 6 papers in Immunology. Recurrent topics in Michelle A. Blaskovich's work include Protein Kinase Regulation and GTPase Signaling (16 papers), Cancer-related Molecular Pathways (9 papers) and Peptidase Inhibition and Analysis (7 papers). Michelle A. Blaskovich is often cited by papers focused on Protein Kinase Regulation and GTPase Signaling (16 papers), Cancer-related Molecular Pathways (9 papers) and Peptidase Inhibition and Analysis (7 papers). Michelle A. Blaskovich collaborates with scholars based in United States, United Kingdom and Australia. Michelle A. Blaskovich's co-authors include Saı̈d M. Sebti, Jiazhi Sun, Andrew D. Hamilton, Richard Jove, James Turkson, Yimin Qian, Alan Cantor, Domenico Coppola, Junko Ohkanda and Andreas Vogt and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Michelle A. Blaskovich

44 papers receiving 3.2k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity

2007 616 citations Michelle A. Blaskovich, Harshani R. Lawrence et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michelle A. Blaskovich United States	27	1.9k	1.4k	545	454	360	44	3.3k
Harshani R. Lawrence United States	35	2.1k 1.1×	1.3k 0.9×	683 1.3×	369 0.8×	283 0.8×	75	3.5k
Jiazhi Sun United States	23	2.2k 1.2×	1.2k 0.9×	322 0.6×	308 0.7×	355 1.0×	42	3.3k
Steven W. Elmore United States	24	3.2k 1.7×	1.2k 0.9×	623 1.1×	716 1.6×	309 0.9×	37	4.8k
Angelika M. Burger United States	37	2.7k 1.4×	981 0.7×	297 0.5×	491 1.1×	684 1.9×	81	4.1k
Ali Bettaı̈eb France	39	2.2k 1.1×	733 0.5×	727 1.3×	274 0.6×	339 0.9×	132	4.0k
Chung-Wai Shiau Taiwan	37	2.1k 1.1×	957 0.7×	374 0.7×	402 0.9×	560 1.6×	68	3.4k
Olivier Sordet France	36	3.3k 1.7×	1.2k 0.8×	384 0.7×	213 0.5×	665 1.8×	52	4.0k
Dayong Zhai United States	36	3.0k 1.6×	667 0.5×	751 1.4×	443 1.0×	336 0.9×	80	4.2k
Ker Yu United States	36	3.3k 1.7×	631 0.5×	477 0.9×	800 1.8×	570 1.6×	84	4.5k
Marzia Pennati Italy	32	2.4k 1.3×	906 0.7×	327 0.6×	355 0.8×	735 2.0×	64	3.4k

Countries citing papers authored by Michelle A. Blaskovich

Since Specialization

Citations

This map shows the geographic impact of Michelle A. Blaskovich's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michelle A. Blaskovich with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michelle A. Blaskovich more than expected).

Fields of papers citing papers by Michelle A. Blaskovich

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michelle A. Blaskovich. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michelle A. Blaskovich. The network helps show where Michelle A. Blaskovich may publish in the future.

Co-authorship network of co-authors of Michelle A. Blaskovich

This figure shows the co-authorship network connecting the top 25 collaborators of Michelle A. Blaskovich. A scholar is included among the top collaborators of Michelle A. Blaskovich based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michelle A. Blaskovich. Michelle A. Blaskovich is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Blaskovich, Michelle A., et al.. (2013). Lysophosphatidic Acid Acyltransferase Beta Regulates mTOR Signaling. PLoS ONE. 8(10). e78632–e78632. 19 indexed citations

Hast, Michael A., Steven Fletcher, Michelle A. Blaskovich, et al.. (2009). Structural Basis for Binding and Selectivity of Antimalarial and Anticancer Ethylenediamine Inhibitors to Protein Farnesyltransferase. Chemistry & Biology. 16(2). 181–192. 29 indexed citations

Epling‐Burnette, Pearlie K., Lubomir Sokol, Xianhong Chen, et al.. (2008). Clinical improvement by farnesyltransferase inhibition in NK large granular lymphocyte leukemia associated with imbalanced NK receptor signaling. Blood. 112(12). 4694–4698. 33 indexed citations

Bai, Fanqi, JianXiang Zou, Wei Sheng, et al.. (2007). Th2 Polarization Induced by the Farnesyltransferase Inhibitor Tipifarnib (Zarnestra®, R115777) through Suppression of T-bet.. Blood. 110(11). 1331–1331. 1 indexed citations

Ohkanda, Junko, Corey L. Strickland, Michelle A. Blaskovich, et al.. (2006). Structure-based design of imidazole-containing peptidomimetic inhibitors of protein farnesyltransferase. Organic & Biomolecular Chemistry. 4(3). 482–482. 9 indexed citations

Peng, Hairuo, et al.. (2006). Synthesis and evaluation of potent, highly-selective, 3-aryl-piperazinone inhibitors of protein geranylgeranyltransferase-I. Organic & Biomolecular Chemistry. 4(9). 1768–1768. 43 indexed citations

Nefedova, Yulia, Pingyan Cheng, Daniele M. Gilkes, et al.. (2005). Activation of Dendritic Cells via Inhibition of Jak2/STAT3 Signaling. The Journal of Immunology. 175(7). 4338–4346. 164 indexed citations

Sun, Jiazhi, De-an Wang, Rishi K. Jain, et al.. (2005). Inhibiting angiogenesis and tumorigenesis by a synthetic molecule that blocks binding of both VEGF and PDGF to their receptors. Oncogene. 24(29). 4701–4709. 87 indexed citations

Sun, Jiazhi, Michelle A. Blaskovich, Richard Jove, et al.. (2005). Cucurbitacin Q: a selective STAT3 activation inhibitor with potent antitumor activity. Oncogene. 24(20). 3236–3245. 228 indexed citations

10.

Ohkanda, Junko, Howard Kendrick, Kohei Yokoyama, et al.. (2004). In vitro and in vivo antimalarial activity of peptidomimetic protein farnesyltransferase inhibitors with improved membrane permeability. Bioorganic & Medicinal Chemistry. 12(24). 6517–6526. 35 indexed citations

11.

Blaskovich, Michelle A., et al.. (2004). Design, synthesis, and evaluation of potent and selective benzoyleneurea-based inhibitors of protein geranylgeranyltransferase-I. Bioorganic & Medicinal Chemistry. 13(3). 677–688. 11 indexed citations

12.

Ohkanda, Junko, Michelle A. Blaskovich, Saı̈d M. Sebti, & Andrew D. Hamilton. (2003). The development of protein farnesyltransferase inhibitors as signaling-based anticancer agents.. PubMed. 5. 211–7. 4 indexed citations

13.

Ohkanda, Junko, David B. Knowles, Michelle A. Blaskovich, Saı̈d Sebti, & Andrew D. Hamilton. (2002). Inhibitors of Protein Farnesyltransferase as Novel Anticancer Agents. Current Topics in Medicinal Chemistry. 2(3). 303–323. 66 indexed citations

14.

Ohkanda, Junko, Jeffrey W. Lockman, Kohei Yokoyama, et al.. (2001). Peptidomimetic inhibitors of protein farnesyltransferase show potent antimalarial activity. Bioorganic & Medicinal Chemistry Letters. 11(6). 761–764. 61 indexed citations

15.

Johnson, B. A., Michelle A. Blaskovich, Valerian E. Kagan, et al.. (2000). Prenyltransferase inhibitors block superoxide production by pulmonary vascular smooth muscle. American Journal of Physiology-Lung Cellular and Molecular Physiology. 278(2). L329–L334. 10 indexed citations

16.

Sun, Jiazhi, Michelle A. Blaskovich, David B. Knowles, et al.. (1999). Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: combination therapy with the cytotoxic agents cisplatin, Taxol, and gemcitabine.. PubMed. 59(19). 4919–26. 175 indexed citations

17.

Kucich, Umberto, Joan C. Rosenbloom, Joan C. Rosenbloom, et al.. (1998). Requirement for Geranylgeranyl Transferase I and Acyl Transferase in the TGF-β-Stimulated Pathway Leading to Elastin mRNA Stabilization. Biochemical and Biophysical Research Communications. 252(1). 111–116. 21 indexed citations

18.

Xu, Xiaoqin, Terence F. McGuire, Michelle A. Blaskovich, Saı̈d M. Sebti, & Guillermo Romero. (1996). Lovastatin Inhibits the Stimulation of Mitogen-Activated Protein Kinase by Insulin in HIRcB Fibroblasts. Archives of Biochemistry and Biophysics. 326(2). 233–237. 37 indexed citations

19.

Lerner, Edwina C., Yimin Qian, Michelle A. Blaskovich, et al.. (1995). Ras CAAX Peptidomimetic FTI-277 Selectively Blocks Oncogenic Ras Signaling by Inducing Cytoplasmic Accumulation of Inactive Ras-Raf Complexes. Journal of Biological Chemistry. 270(45). 26802–26806. 314 indexed citations

20.

Vogt, Andreas, Yimin Qian, Michelle A. Blaskovich, et al.. (1995). A Non-peptide Mimetic of Ras-CAAX: Selective Inhibition of Farnesyltransferase and Ras Processing. Journal of Biological Chemistry. 270(2). 660–664. 95 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact